这里有一篇文章解释

来源: viewfinder 2016-09-09 15:09:28 [] [博客] [旧帖] [给我悄悄话] 本文已被阅读: 次 (2281 bytes)

http://www.medscape.com/viewarticle/841669#vp_1

"The incremental innovation has repeatedly precluded the formation of a generic insulin industry in North America when earlier patents expired. The history of insulin hasn't followed the standard chronology of pharmaceutical innovation, in which patent monopolies predictably give way to generic competition."

Indeed, "insulin is not a single entity but a family of related products that has evolved through incremental improvements. Subsequent iterations of insulin represented actual innovations, each one being safer, more effective, or more convenient than its predecessor."

Because of that, "generic drug manufacturers are unlikely to invest in producing older versions of insulin that may already be obsolete," Drs Greene and Riggs observe.

 

And this is the case despite the fact that studies don't consistently show that analogs produce better outcomes than do the older NPH and regular insulins, and the advantages should be weighed against the costs, particularly for patients without adequate health insurance.

 

所有跟帖: 

有意思,跟蔷薇说的一样。能用二甲双胍的用二甲双胍,不能用的减肥省钱吧。 -吃与活- 给 吃与活 发送悄悄话 吃与活 的博客首页 (0 bytes) () 09/09/2016 postreply 16:18:05

1型的没办法,不发达国家1型的多。 -viewfinder- 给 viewfinder 发送悄悄话 viewfinder 的博客首页 (0 bytes) () 09/09/2016 postreply 16:31:38

请您先登陆,再发跟帖!

发现Adblock插件

如要继续浏览
请支持本站 请务必在本站关闭/移除任何Adblock

关闭Adblock后 请点击

请参考如何关闭Adblock/Adblock plus

安装Adblock plus用户请点击浏览器图标
选择“Disable on www.wenxuecity.com”

安装Adblock用户请点击图标
选择“don't run on pages on this domain”